The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor
Abstract
Despite an initial response to androgen deprivation therapy, prostate cancer (PCa) progresses eventually from an androgen-dependent to an androgen-independent phenotype. One of the mechanisms of relapse is antiandrogen withdrawal phenomenon caused by mutation of 877th amino acid of androgen receptor (AR). In the present study, we established a method to measure the concentration of androstenediol (adiol) in prostate tissue. We found that adiol maintains a high concentration in PCa tissue even after androgen deprivation therapy. Furthermore, adiol is a stronger activator of mutant AR in LNCaP PCa cells and induces more cell proliferation, prostate-specific antigen (PSA) mRNA expression, and PSA promoter than dihydrotestosterone (DHT). Because antiandrogen, bicalutamide, blocked adiol activity in LNCaP cells, it was suggested that adiol effect was mediated through AR. However, high concentration of bicalutamide was necessary to block completely adiol activity. These effects were specific to LNCaP cells because adiol had less effect in PC-3 PCa cells transfected with wild-type AR than DHT and had similar effect in PC-3 cells transfected with mutant AR. The mechanism that adiol activates mutant AR in LNCaP cells did not result from the increased affinity to mutant AR or from AR’s association with coactivator ARA70. However, low concentration of adiol induced more AR nuclear translocation than DHT in LNCaP cells and not PC-3 cells transfected with AR. These results indicate that adiol may cause the progression of PCa even after hormone therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Labrie, F., Luu-The, V, Lin, S., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., & Belanger, A. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250001 · Cited by 278
Discrimination between NL1- and NL2-Mediated Nuclear Localization of the Glucocorticoid Receptor
Savory, J. G. A., Hsu, B., Laquian, I. R., Giffin, W., Reich, T., Haché, R. J. G., & Lefebvre, Y. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1025 · Cited by 222
Liganded Androgen Receptor Interaction with β-Catenin
Pawlowski, J. E., Ertel, J. R., Allen, M. P., Xu, M., Butler, C., Wilson, E. M., & Wierman, M. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200545200 · Cited by 166
Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer.
BÉLANGER, A., BROCHU, M., & CLICHE, J. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-5-812 · Cited by 108
Cited by
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 389
Yuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2014) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 370
Novel 5α‐steroid reductase (SRD5A3, type‐3) is overexpressed in hormone‐refractory prostate cancer
Uemura, M., Tamura, K., Chung, S., Honma, S., Okuyama, A., Nakamura, Y., & Nakagawa, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00656.x · Cited by 263
Self-citation
Metadata
- Authors
- Mizokami, A., Koh, E., Fujita, H., Maeda, Y., Egawa, M., Koshida, K., Honma, S., Keller, E. T., & Namiki, M.
- Venue
- Cancer Research
- Published
- 2004-01-15
- Volume
- 64
- Issue
- 2
- Pages
- 765-771
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2167634604
- Cited by
- 175
- References
- 4
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-0130
- The paper
- Mizokami, A., Koh, E., Fujita, H., Maeda, Y., Egawa, M., Koshida, K., Honma, S., Keller, E. T., & Namiki, M. (2004). The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-0130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.